IMNM insider trading
NasdaqCM HealthcareImmunome Inc.: insider trade history from SEC Form 4 filings.
About Immunome Inc.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Company website: immunome.com
IMNM insider activity at a glance
FilingIQ tracks 115 insider transactions for IMNM in filings since Oct 8, 2020. The most recent transaction is dated Sep 11, 2026.
Across the full history, 42 open-market purchases
and 30 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on IMNM insider trades is 54.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest IMNM Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for IMNM?
- FilingIQ tracks 115 Form 4 insider transactions for IMNM (Immunome Inc.), covering filings from Oct 8, 2020 onwards. 18 of those are dated within the last 90 days.
- Are IMNM insiders net buyers or net sellers?
- Across the full Form 4 history for IMNM, 42 transactions (37%) were open-market purchases and 30 (26%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does IMNM insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is IMNM in?
- Immunome Inc. (IMNM) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.47B.
Methodology & sources
Every IMNM insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.